PL3946322T3 - Sposoby przywracania wrażliwości na ttfields w komórkach nowotworowych opornych wobec ttfields, z inhibitorami ptger3 - Google Patents

Sposoby przywracania wrażliwości na ttfields w komórkach nowotworowych opornych wobec ttfields, z inhibitorami ptger3

Info

Publication number
PL3946322T3
PL3946322T3 PL20717971.4T PL20717971T PL3946322T3 PL 3946322 T3 PL3946322 T3 PL 3946322T3 PL 20717971 T PL20717971 T PL 20717971T PL 3946322 T3 PL3946322 T3 PL 3946322T3
Authority
PL
Poland
Prior art keywords
ttfields
ptger3
inhibitors
methods
cancer cells
Prior art date
Application number
PL20717971.4T
Other languages
English (en)
Inventor
David Tran
Son Bang LE
Dongjiang CHEN
Original Assignee
Novocure Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novocure Gmbh filed Critical Novocure Gmbh
Publication of PL3946322T3 publication Critical patent/PL3946322T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/20Applying electric currents by contact electrodes continuous direct currents
    • A61N1/205Applying electric currents by contact electrodes continuous direct currents for promoting a biological process
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20717971.4T 2019-03-29 2020-03-27 Sposoby przywracania wrażliwości na ttfields w komórkach nowotworowych opornych wobec ttfields, z inhibitorami ptger3 PL3946322T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826078P 2019-03-29 2019-03-29
US201962849535P 2019-05-17 2019-05-17
PCT/IB2020/052959 WO2020201967A1 (en) 2019-03-29 2020-03-27 Methods for restoring sensitivity to ttfields in ttfields-resistant cancer cells with ptger3 inhibitors

Publications (1)

Publication Number Publication Date
PL3946322T3 true PL3946322T3 (pl) 2024-02-26

Family

ID=70228406

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20717971.4T PL3946322T3 (pl) 2019-03-29 2020-03-27 Sposoby przywracania wrażliwości na ttfields w komórkach nowotworowych opornych wobec ttfields, z inhibitorami ptger3

Country Status (7)

Country Link
US (1) US11911610B2 (pl)
EP (3) EP3977991A1 (pl)
JP (2) JP7419391B2 (pl)
CN (1) CN113613651A (pl)
DK (1) DK3946322T3 (pl)
PL (1) PL3946322T3 (pl)
WO (1) WO2020201967A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10779875B2 (en) 2013-05-06 2020-09-22 Novocure Gmbh Optimizing treatment using TTfields by changing the frequency during the course of long term tumor treatment
US10188851B2 (en) 2015-10-28 2019-01-29 Novocure Limited TTField treatment with optimization of electrode positions on the head based on MRI-based conductivity measurements
US10821283B2 (en) 2016-04-04 2020-11-03 Novocure Gmbh Reducing motility of cancer cells using tumor treating fields (TTFields)
US11573221B2 (en) 2017-01-19 2023-02-07 Novocure Gmbh System for viewing cell cultures under a microscope whilst applying TTFields
US11986647B2 (en) 2018-09-07 2024-05-21 Novocure Gmbh Treating autoinflammatory and mitochondrial diseases using an alternating electric field
WO2020079554A1 (en) 2018-10-15 2020-04-23 Zeev Bomzon Generating tumor treating fields (ttfields) with high uniformity throughout the brain
EP3922300B1 (en) 2018-11-19 2024-03-06 Novocure GmbH Arrays for delivering tumor treating fields (ttfields) with selectively addressable sub-elements
US11224741B2 (en) 2018-11-29 2022-01-18 Novocure Gmbh Enhanced-flexibility transducer arrays for delivering TTFields (tumor treating fields)
EP3909015A1 (en) 2019-01-08 2021-11-17 Novocure GmbH Evaluating quality of segmentation of an image into different types of tissue for planning treatment using tumor treating fields (ttfields)
US11654279B2 (en) 2019-07-31 2023-05-23 Novocure Gmbh Applying tumor treating fields (TTFields) via electrodes embedded into skull implants
CN114364433A (zh) 2019-08-30 2022-04-15 诺沃库勒有限责任公司 向颈部输送肿瘤治疗场(TTFields)
CN114901344A (zh) 2019-12-31 2022-08-12 诺沃库勒有限责任公司 具有可单独访问的电极元件和温度传感器的用于传递肿瘤治疗场(tt场)的阵列
CA3163315A1 (en) 2019-12-31 2021-07-08 Novocure Gmbh High voltage, high efficiency sine wave generator that prevents spikes during amplitude adjustments and switching of channels
US11818943B2 (en) 2020-06-25 2023-11-14 Novocure Gmbh Fabricating organic light emitting diodes (OLEDs) using tubulin
US20220267445A1 (en) * 2021-02-17 2022-08-25 Novocure Gmbh Methods and Compositions for Determining Susceptibility to Treatment with Checkpoint Inhibitors
WO2024062456A1 (en) 2022-09-23 2024-03-28 Novocure Gmbh 3d models for predicting treatment responses to alternating electric fields

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8447395B2 (en) 2000-02-17 2013-05-21 Novocure Ltd Treating bacteria with electric fields
US6868289B2 (en) 2002-10-02 2005-03-15 Standen Ltd. Apparatus for treating a tumor or the like and articles incorporating the apparatus for treatment of the tumor
CN1416466A (zh) 2000-02-17 2003-05-07 约朗姆·帕尔蒂 破坏正在分裂的细胞的方法和装置
US7599746B2 (en) 2000-02-17 2009-10-06 Standen Ltd Apparatus and method for preventing the spread of cancerous metastases and for elimination of metastases
US8175698B2 (en) 2000-02-17 2012-05-08 Novocure Ltd. Treating bacteria with electric fields
US7016725B2 (en) 2001-11-06 2006-03-21 Standen Ltd. Method and apparatus for destroying dividing cells
US7089054B2 (en) 2002-10-02 2006-08-08 Standen Ltd. Apparatus and method for treating a tumor or the like
US7136699B2 (en) 2002-10-02 2006-11-14 Standen, Ltd. Apparatus for destroying dividing cells
WO2005115535A2 (en) 2004-04-23 2005-12-08 Novocure Ltd. Treating a tumor or the like with electric fields at different frequencies
EP2161054B1 (en) 2004-12-07 2015-12-02 Novocure Limited Electrodes for applying an electric field in-vivo over an extended period of time
CN102488967B (zh) 2004-12-27 2016-03-30 诺沃库勒有限公司 利用电场从不同方向治疗肿瘤等
CN101321555B (zh) 2005-10-03 2020-12-08 诺沃库勒有限责任公司 优化电场特征以增加电场在增殖细胞上的效果
US8019414B2 (en) 2006-04-05 2011-09-13 Novocure Ltd. Treating cancer using electromagnetic fields in combination with other treatment regimens
US20100074896A1 (en) 2006-11-30 2010-03-25 The Johns Hopkins University Antagonists of pge2 ep3 receptors
EP3231480A1 (en) 2007-03-06 2017-10-18 Novocure Ltd. Treating cancer using electromagnetic fields in combination with photodynamic therapy
CA2696352C (en) 2007-08-14 2017-03-21 Novocure Limited Treating parasites with electric fields
US8715203B2 (en) 2007-09-17 2014-05-06 Novocure Limited Composite electrode
ES2628580T3 (es) * 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de decitabina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer el tratamiento de cáncer
US9381176B2 (en) 2012-02-24 2016-07-05 Wisconsin Alumni Research Foundation E-prostanoid receptor, Ptger3, as a novel anti-diabetic therapeutic target
US9655669B2 (en) 2013-05-06 2017-05-23 Novocure Limited Optimizing treatment using TTFields by changing the frequency during the course of long term tumor treatment
US10779875B2 (en) 2013-05-06 2020-09-22 Novocure Gmbh Optimizing treatment using TTfields by changing the frequency during the course of long term tumor treatment
US20190117963A1 (en) 2014-07-25 2019-04-25 Loyalty Based Innovations, LLC Apparatus and method for treating multiple tumors in patients with metastatic disease by electric fields
US9910453B2 (en) 2015-09-25 2018-03-06 Novocure Limited High voltage, high efficiency sine wave generator with pre-set frequency and adjustable amplitude
US10188851B2 (en) 2015-10-28 2019-01-29 Novocure Limited TTField treatment with optimization of electrode positions on the head based on MRI-based conductivity measurements
US10821283B2 (en) 2016-04-04 2020-11-03 Novocure Gmbh Reducing motility of cancer cells using tumor treating fields (TTFields)
KR102555691B1 (ko) 2016-06-30 2023-07-13 노보큐어 리미티드 신체에 대한 종양 치료장의 길이 방향 전달을 위한 어레이들
US20180008708A1 (en) 2016-07-10 2018-01-11 Novocure Limited Synchronizing Tumor Cells to the G2/M Phase Using TTFields Combined with Taxane or Other Anti-Microtubule Agents
DK3500334T3 (da) 2016-08-18 2023-10-09 Novocure Gmbh Temperaturmåling i arrays til levering af ttfields
ES2916252T3 (es) 2016-12-13 2022-06-29 Novocure Gmbh Tratamiento de pacientes con campos TT con las posiciones de los electrodos optimizadas utilizando plantillas deformables
US11573221B2 (en) 2017-01-19 2023-02-07 Novocure Gmbh System for viewing cell cultures under a microscope whilst applying TTFields
TWI676483B (zh) * 2017-08-06 2019-11-11 強普生技股份有限公司 醫藥套組及其用途
JP7139448B2 (ja) 2018-04-09 2022-09-20 ノボキュア ゲーエムベーハー TTFields及びオーロラキナーゼ阻害剤による腫瘍の治療
KR20200141478A (ko) 2018-04-10 2020-12-18 지브 봄존 서로 다른 반복 시간을 가지는 두 개의 MRI 이미지들로부터 얻어진 1MHz 미만 저주파 교류 전도도 추산치
US20200009376A1 (en) 2018-07-03 2020-01-09 Edwin Chang Using Alternating Electric Fields to Increase Cell Membrane Permeability
US11179322B2 (en) 2018-07-10 2021-11-23 Novocure Gmbh Methods and compositions for treating tumors with TTFields and sorafenib
KR102607603B1 (ko) 2018-07-18 2023-11-29 노보큐어 게엠베하 종양 치료장의 용량을 정량화하기 위한 전력 손실 밀도 및 관련 측정값의 사용
JP6974671B2 (ja) 2018-08-23 2021-12-01 ノボキュア ゲーエムベーハー 血液脳関門の透過性を向上させるための交流電界の使用
US11160977B2 (en) 2018-09-04 2021-11-02 Novocure Gmbh Delivering tumor treating fields (TTFields) to the infratentorial brain
EP3846894A1 (en) 2018-09-07 2021-07-14 Novocure GmbH Treating autoimmune diseases using an alternating electric field to reduce the proliferation of t-cells
US20200108031A1 (en) 2018-10-05 2020-04-09 Novocure Gmbh Treating Tumors Using TTFields Combined with ABT-751
JP7282411B2 (ja) 2018-10-23 2023-05-29 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 交流電場を使用する、幹細胞に基づく療法におけるテラトーマ形成の予防及び処置
CN112955208A (zh) 2018-10-25 2021-06-11 吉夫·波姆桑 向受试者的脊柱解剖结构递送交变电场(例如,ttfields)
US20200146586A1 (en) 2018-11-14 2020-05-14 Novocure Gmbh Creating Accurate Computational Head Models of Patients Using Datasets Combining MRI and CT Images
EP3922300B1 (en) 2018-11-19 2024-03-06 Novocure GmbH Arrays for delivering tumor treating fields (ttfields) with selectively addressable sub-elements
US11224741B2 (en) 2018-11-29 2022-01-18 Novocure Gmbh Enhanced-flexibility transducer arrays for delivering TTFields (tumor treating fields)
EP3909015A1 (en) 2019-01-08 2021-11-17 Novocure GmbH Evaluating quality of segmentation of an image into different types of tissue for planning treatment using tumor treating fields (ttfields)

Also Published As

Publication number Publication date
EP3988099A1 (en) 2022-04-27
CN113613651A (zh) 2021-11-05
JP2023171933A (ja) 2023-12-05
DK3946322T3 (da) 2023-11-27
EP3988099B1 (en) 2023-06-07
JP2022524824A (ja) 2022-05-10
EP3946322A1 (en) 2022-02-09
US11911610B2 (en) 2024-02-27
EP3977991A1 (en) 2022-04-06
EP3946322B1 (en) 2023-09-20
US20200306531A1 (en) 2020-10-01
WO2020201967A1 (en) 2020-10-08
JP7419391B2 (ja) 2024-01-22
EP3988099C0 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
EP3988099C0 (en) METHODS OF RESTORING SENSITIVITY TO TUMOR TREATMENT FIELDS IN CANCER CELLS RESISTANT TO TUMOR TREATMENT FIELDS WITH PTGER3 INHIBITORS
HK1216473A1 (zh) 動態頻譜仲裁系統中的小區選擇
EP3328896A4 (en) HEMATOPOIETIC STEM CELLS IN COMBINATORY THERAPY WITH IMMUNCHECKPOINT INHIBITORS AGAINST CANCER
EP3480321B8 (en) Massively parallel single cell analysis
EP2964672A4 (en) SPECIFIC DETECTION TOOL FOR MESENCHYMES AND EPITHELIC MESENCHYMAL TRANSFORMED CIRCULATING TUMOR CELLS
IL246083A0 (en) A barrier inhibitor and a whole mycobacterium cell, for use in cancer treatment
TWI562171B (en) The composition for forming solar cell electrode and electrode prepared using the same
IN2015DN00143A (pl)
EP2963432A4 (en) DEVICE FOR ASSESSING THE EXTENT OF DAMAGE IN A SECONDARY CELL
EP2943591A4 (en) METHOD AND COMPOSITIONS FOR PROFILING SINGLE CELL EXPRESSION
EP3701045A4 (en) IMPROVEMENTS TO OR RELATING TO CELLAL ANALYSIS
GB201417240D0 (en) Solar cell with specific front surface electrode design
EP3523416A4 (en) METHODS AND COMPOSITIONS ASSOCIATED WITH ANTI-CANCER THERAPIES OF NK AND ANTI-PDL1 CELLS
EP3342414A4 (en) MEANS FOR IMPROVING ATP IN CELLS
EP3565308A4 (en) METHOD AND DEVICE FOR RECORDING WITH A CELL
EP3088526A4 (en) Use of mirna-214 inhibitor in inhibiting regulatory t cells
EP3439688A4 (en) COMPOSITIONS AND METHODS IN CONNECTION WITH POLYCYTOTOXIC T CELLS
HK1221504A1 (zh) 用於前列腺癌的生物標誌物檢測中的方法和陣列
EP3294334A4 (en) Autoimmune antibodies for use in inhibiting cancer cell growth
EP3047275A4 (en) Compositions and methods for increasing mesenchymal stromal cell migration to tumors
EP3125341A4 (en) Lead storage cell and electrode collector for lead storage cell
FR3007201B1 (fr) Cellule solaire multi-jonctions
SG11201506423RA (en) Ion tolerant corrosion inhibitors and inhibitor combinations for fuels
EP3259782A4 (en) Damage buffer for solar cell metallization
PL3475359T3 (pl) Hydrolitycznie stabilne kompozycje do folii w ogniwach słonecznych